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Abstract
Introduction: The application of high-throughput genomic approaches has revealed 24 novel risk loci for Alzheimer’s
disease (AD). We recently reported that the bridging integrator 1 (BIN1) risk gene is linked to Tau pathology.
Results: We used glutathione S-transferase pull-down assays and nuclear magnetic resonance (NMR) experiments to
demonstrate that BIN1 and Tau proteins interact directly and then map the interaction between BIN1’s SH3
domain and Tau’s proline-rich domain (PRD) . Our NMR data showed that Tau phosphorylation at Thr231
weakens the SH3-PRD interaction. Using primary neurons, we found that BIN1-Tau complexes partly co-localize with
the actin cytoskeleton; however, these complexes were not observed with Thr231-phosphorylated Tau species.
Conclusion: Our results show that (i) BIN1 and Tau bind through an SH3-PRD interaction and (ii) the interaction is
downregulated by phosphorylation of Tau Thr231 (and potentially other residues). Our study sheds new light on
regulation of the BIN1/Tau interaction and opens up new avenues for exploring its complex’s role in the pathogenesis
of AD.
Introduction
Alzheimer’s disease (AD) is a progressive, neurodegener-
ative disorder characterized by (i) the massive loss of
neurons in several regions of the brain. There are two
distinct types of lesion: intraneuronal neurofibrillary
tangles (NFTs, composed of abnormally phosphory-
lated Tau proteins) and extracellular amyloid deposits
(composed of amyloid-β peptide (Aβ)). Mutations in
the genes for amyloid precursor protein (APP), presenilin-
1 and presenilin-2 are responsible for rare, autosomal-
dominant forms of AD. The discovery of these mutations
prompted the amyloid cascade hypothesis, which has rad-
ically changed our understanding of AD; APP metabolism
and Aβ peptide production/degradation are thought to
have a key role in the pathogenesis of AD (or at least the
rare, familial forms of AD) [1]. However, the validity of this
hypothesis in the vast majority of cases of AD (the so-called
sporadic form) is subject to debate. Since 2009, the applica-
tion of high-throughput genomic approaches has led to the
characterization of 24 additional genetic risk factors for
sporadic AD (following on from the apolipoprotein E
(APOE) gene, which was characterized as a major genetic
risk factor in 1993) [2]. We recently reported that the bridg-
ing integrator 1 (BIN1) gene is the first of these new genetic
determinants for sporadic AD with a clear link to Tau path-
ology and (potentially) neurofibrillary degeneration [3]. We
found that BIN1 was upregulated in the brains of AD cases
and that a functional variant modulating BIN1 expression
was associated with NFT loads. We were also able to show
that BIN1 and Tau were directly interacting together in
vitro and that human Tau toxicity observed in Drosophila
melanogaster was partly suppressed by the silencing of the
Drosophila BIN1 ortholog [3]. Taken as a whole, these data
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suggest that BIN1 interacts with Tau and is involved in
Tau pathology. We therefore decided to characterize the
BIN1-Tau interaction and the latter’s putative regulatory
mechanisms in more detail. In the present work, we used
glutathione S-transferase (GST) pull-down and nuclear
magnetic resonance (NMR) experiments to show that
BIN1’s SH3 domain interacts with Tau’s proline-rich
domain (PRD). We found that amino acids [212–231] in
Tau are essential for this interaction, and that phosphoryl-
ation within this sequence weakens the binding. Lastly, we
used a proximity ligation assay (PLA) in primary neuron
cultures to show that BIN1-Tau complexes co-localize
with the actin cytoskeleton. However BIN1-Tau com-
plexes were not observed in neurons when Tau Thr231 is
phosphorylated. Taken as a whole, our results provide a
detailed view of the molecular interplay between Tau and
BIN1 and show for the first time that Tau phosphorylation
weakens the interaction between these two proteins.
Materials and methods
cDNA and plasmids
Tau full-length (FL) 2N4R cDNA in pcDNA four was a
kind gift from Luc Buée (INSERM U837, Lille, France).
The BIN1 isoform used in the present study corresponds
to the longest neuronal isoform 1 and will be denoted as
BIN1 FL. For GST pull-down experiments, both Tau FL
and Tau sub-fragment cDNA sequences were obtained by
PCR with the primers described in Additional file 1, and
subcloned into the pGEX-4 T2 vector (General Electric
Healthcare Bio-Sciences, Piscataway, NJ, USA) to produce
GST-Tau constructs. GST BIN1 FL and GST-BIN1/SH3
were obtained as previously described [4]. BIN1/ΔSH3
cDNA sequence was obtained by PCR from BIN1 FL
cDNA (NM_139343.1) in PCMV6-XL5 (Origene, Rock-
ville, MD, USA). For NMR experiments, the BIN1/SH3
domain cDNA was synthesized with optimized codons for
recombinant expression in E. coli (Genecust, Dudelange,
Luxembourg). The cDNA was subcloned between the
NdeI and XhoI restriction sites in pET15b (Novagen,
EMD Millipore, Darmstadt, Germany), thus allowing its
expression with an N-terminal HisTag under the control
of a T7 promoter. Recombinant Tau-F5[165-245] and
TauFL were prepared for NMR experiments without a N-
terminal tag with a pET15B vector. All cDNAs were
checked by sequencing.
Cell cultures and transfection
Human embryonic kidney 293 (HEK293) cells (CRL-1573
from LGC Standards/American Type Culture Collection,
Molsheim, France) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM)/F12 (1:1) supplemented with
10 % fetal bovine serum, 2 mM glutamine, 20 units/ml
penicillin and 20 μg/ml streptomycin (Gibco, LifeTechnol-
ogies, Carlsbad, CA, USA) in 5 % CO2 atmosphere and at
37 °C. Transient transfections were performed using
Fugene-HD (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. Forty-eight hours later,
cells were harvested in Tris-buffered saline (100 mM
NaCl, 1 mM EDTA, 50 mM Tris–HCl) and centrifuged at
1000 g for 10 min at room temperature. Cell pellets were
stored at−80 °C until processing for GST pull-down.
The GST pull-down assay
The GST fusion proteins were expressed in Escherichia
coli BL21(DE3) after induction with isopropyl 1-thio-β-
D-galactopyranoside. Proteins were extracted from bac-
terial inclusion bodies by incubation with lysosyme for
1 h, overnight incubation with N-sarkosyl (0.001 %) and
Triton X-100 (0.5 %), sonication and then centrifugation
at 12,500 g for 30 min. All steps were performed at 4 °C.
The GST fusion proteins were immobilized on glutathione-
Sepharose beads (Pierce, ThermoFisher Scientific, Rockford,
IL USA) according to the manufacturer’s instructions, and
then incubated with HEK293 cell lysates for 1 h at room
temperature. Beads were washed in Tris buffered saline,
centrifuged at 10,500 g for 1 min and processed for
SDS-PAGE analysis.
Isotopic labelling and protein purification
Isotopic labelling of Tau and Tau-F5 was performed by
growing recombinant BL21 (DE3) in minimal growth
medium supplemented with 15N NH4Cl. The first purifi-
cation step was performed by heating the bacterial pro-
tein extract for 15 min at 75 °C. The 15N Tau protein
and 15N Tau[165–245] were recovered in the soluble
fraction after centrifugation at 15,000 g for 30 min. The
15N Tau protein and 15N Tau-F5 were purified by cation
exchange chromatography in 50 mM phosphate buffer
pH 6.3, 1 mM EDTA (5 ml Hitrap SP Sepharose FF,
General Electric Healthcare, Little Chalfont, United
Kingdom). The pooled fractions from the chromatog-
raphy purification step were transferred to ammonium
bicarbonate by desalting on a 15/60 Hiprep desalting
column (G25 resin, General Electric Healthcare) and
lyophilized. The His-SH3 protein was purified on Ni-NTA
resin, according to the manufacturer’s protocol.
Acquisition and analysis of NMR spectra
1 mM d4-TMSP (3-(trimethylsilyl) propionate was used
as an internal reference for proton chemical shifts (CSs)
(0 ppm). The NMR buffer was 25 mM Tris-d11 pH 6.6,
30 mM NaCl, 2.5 mM EDTA and 1 mM DTT and 5 %
D2O. Two-dimensional [
1H, 15N] heteronuclear single
quantum coherence (HSQC) spectra were recorded at
298 K on a Bruker 900 spectrometer equipped with a
triple-resonance cryogenic probe (Bruker, Karlsruhe,
Germany). Spectra were processed using Bruker Top-
Spin software (version 2.1, Bruker, Karlsruhe, Germany),
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and peaks were picked using Sparky software (version 3,
T. D. Goddard and D. G. Kneller, University of California,
San Francisco, CA, USA). The delta (δ) CSs of indi-
vidual amide resonances of Tau-F5 and Tau FL were
calculated with the following equation, while taking
account of the relative dispersion of the proton and
nitrogen CSs: δ(CS) = [((CS1Hbound- CS
1Hfree) + 0.2
(CS15Nbound- CS
15Nfree))
2]1/2. The “bound” and “free”
subscripts in the equation correspond to the CSs in
the SH3-bound protein or the free protein, respectively.
Phosphorylation of Tau protein
The CDK2/CycA3 protein was prepared and Tau was
phosphorylated in vitro as previously described [5]. En-
zymatic reactions were terminated by heating for 15 min
at 75 °C and then centrifuged. The phosphorylation
mixture was buffer-exchanged for NMR buffer using
centrifugal desalting columns (Zeba Desalting Columns,
with a 0.5 ml bed of G25 resin and a 7 kDa cut-off
(Thermofisher Scientific, Waltham, MA USA)).
Electrophoresis and Western blots
Samples were resuspended in Lithium Dodecyl Sulfate
buffer supplemented with Nupage antioxidant, heated
for 10 min at 95 °C, loaded and separated on a 4–12 %
acrylamide gel (Nupage, Novex, Life Technologies,
Carlsbad, CA, USA) and blotted on nitrocellulose mem-
branes using a BioRad Trans-Blot transfer system kit
(BioRad, Hercules, CA, USA) according to the manufac-
turer’s instructions. Membranes were blocked and probed
with antibodies diluted at the concentration indicated in
Additional file 2. All antibodies were purchased directly
from the provider (described in Additional file 2), except
for CP13 [6], RZ3 [7] and PHF1 [8]. Membranes were
incubated with a horseradish-peroxidase-conjugated sec-
ondary antibody (Jackson Immunoresearch Laboratories,
West Grove, PA, USA), and revealed by chemilumines-
cence (Luminata ClassicoTM, EMD Millipore) in a BioRad
Chemidoc XRS system (BioRad). Immunoblot data were
quantified with ImageLab software (BioRad). Coomassie
staining was performed with 0.05 % Brilliant Blue G
(mass/volume) in 50 % methanol (vol/vol) and 10 % acetic
acid (v/v). Destaining was performed with a 25 % metha-
nol (v/v) and 7 % acetic acid (v/v) solution.
Immunofluorescence assays and PLAs
Cultured cells were fixed on glass coverslips with either
4 % paraformaldehyde (EMS, Hatfield, PA, USA) in
Phosphate Buffered Saline (PBS) (Life Technologies).
Fixed cells were washed and permeabilized for 10 min in
PBS supplemented with 0.25 % Triton X-100, and then
blocked in PBS supplemented with 2 % bovine serum
albumin for 2 h at room temperature. Coverslips were
incubated overnight at 4 °C with primary antibodies (as
specified in Additional file 2), washed in PBS and incu-
bated for 45 min with Alexa Fluor antibodies diluted at
1/400 from stock (Molecular Probes, Life Technologies).
Alexa Fluor 647 phalloidin (Molecular Probes, Life
Technologies)was used as per the manufacturer’s instruc-
tions to stain the actin cytoskeleton. For PLAs, the initial
steps (from fixation to primary antibody incubation) were
the same as those described above for immunofluores-
cence assays. The following steps (i.e., secondary antibody
incubation, ligation, amplification and probing) were per-
formed according to the manufacturer’s instructions
(Olink Bioscience, Uppsala, Sweden). Images were acquired
with a confocal microscope (LSM 710, Zeiss, Oberkochen,
Germany) and processed using ZEN 2012 software (Zeiss).
Three independent experiments were performed for each
condition. The mean intensity per pixel in three differ-
ent fields was measured using ImageJ software. Imaris
software (Bitplane, Zurich, Switzerland) was used for
three-dimensional (3D) image processing.
Primary neuron cultures
Mixed cortical and hippocampal primary cultures were
obtained from P0 rats, according to previously described
procedures [9]. Briefly, hippocampi and cortices were iso-
lated from newborn rats, and neurons were dissociated by
trypsin digestion. Neurons were plated on poly-L-lysine-
coated coverslips or six-well plates, and were incubated
with Minimal Essential Medium (MEM) supplemented
with 10 % fetal bovine serum, Glutamax, MEM vitamins
and penicillin/streptomycin (Life Technologies), according
to the manufacturer’s instructions. After 24 h, neurons
were transferred into serum-free Neurobasal-A medium
supplemented with B27 (Gibco, Life Technologies), Gluta-
max and uridine-deoxyfluorouridine for 14 days of in vitro
culture. For Western blot analysis, primary neurons were
directly harvested in LDS buffer supplemented with
Nupage antioxidant (Life Technologies) and processed as
described above in the “Electrophoresis and Western
blots” section. For immunofluorescence assays, cells were
fixed in 4 % paraformaldehyde (EMS) and processed as
described above in the “Immunofluorescence assays and
PLAs” section.
Results
BIN1’s SH3 domain interacts with Tau’s PRD
In previous work [3], we evidenced a direct interaction
between full-length BIN1 and Tau in vitro. To further
identify the protein domains involved in this interaction,
we generated various constructs of Tau and BIN1
(Fig. 1a). We first incubated purified GST-Tau FL 1–441
or Tau domains (GST-Tau/N-terminal part (Nter), GST-
Tau/PRD, GST-Tau/microtubule binding domain (MBD))
with HEK293 cell lysates overexpressing BIN1 FL. Only
GST-Tau FL and GST-Tau/PRD pulled down BIN1
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(Fig. 1b, lanes 2 and 4). In contrast, no interaction was
observed with GST-Tau/Nter or (GST-Tau/MBD) (Fig. 1b,
lanes 3 and 5). Secondly, we performed the reciprocal
experiments by incubating Tau-overexpressing HEK293
cell lysates with either GST-BIN1 FL or GST-BIN1/SH3.
In both cases, we observed an interaction with Tau FL
(Fig. 1c). Lastly, we incubated GST-Tau FL or GST-Tau/
PRD with HEK293 lysates overexpressing BIN1 FL or
BIN1 lacking its SH3 domain. Removal of the BIN1 SH3
domain markedly weakened the BIN1-Tau interaction
(Fig. 1d, lanes 4 and 6 vs lanes 3 and 5).
We next used NMR spectroscopy to determine which
a minima sequence in Tau interacts with BIN1. Briefly,
comparison of the 1H, 15N HSQC spectrum of Tau441
(which we and others have fully assigned [10]) with that
of the protein in the presence of GST-BIN1/SH3 domain
revealed perturbations in the CS of several amino acids
(Fig. 1e, f, and Additional file 3). Analysis of the δ CS
([Tau + BIN1/SH3] versus [Tau]) for each Tau amino acid
clearly delimited a short interaction region within the aa
212–231 sequence (Fig. 2f, i). These results were vali-
dated by studying a Tau domain encompassing aa 165 to
245 (Tau-F5) (Fig. 1g, h, and Additional file 4).
In vitro, the BIN1-Tau interaction depends on Tau’s
phosphorylation status
As Tau phosphorylation has been previously shown to
regulate Tau PRD-SH3 interactions [11, 12], we next
looked at whether Tau phosphorylation could interfere
with the BIN1-Tau interaction. We acquired NMR data
after the in vitro phosphorylation of Tau FL or a Tau
fragment (Tau-F5[165–245]) by recombinant kinases
(Fig. 2). Firstly, following in vitro incubation with CDK2/
CycA3 [5], we confirmed that phosphorylation levels
increased at several major Tau phosphoepitopes such as
pT181 (AT270), pS199, pT205, pS202-T205 (AT8, Tau-1)
and pT231 (RZ3, AT180), as shown by immunoblots
(Fig. 2a) and NMR analysis (see Additional file 5). A com-
parison of NMR spectra of CDK2/CycA3-phosphorylated
Tau-FL and Tau-F5 in the presence or absence of BIN1/
SH3 did not reveal any significant CS perturbations. These
findings indicated a lack of interaction between BIN1/SH3
domain and in vitro-phosphorylated Tau-F5 fragment or
Tau-FL (Fig. 2b, c and Additional file 6, Additional file
7). Additional experiments with either a recombinant ERK
kinase (see Additional file 8) or rat brain extract kinases
(see Additional file 9) confirmed these findings. Taken as a
whole, our results demonstrate that Tau phosphorylation
in and around the PRD weakens the BIN1-Tau interaction
by precluding SH3-PRD binding.
BIN1-Tau complexes partly co-localized with the actin
cytoskeleton network
In order to further investigate the significance of BIN1-
Tau binding in a physiological context, we used both
conventional immunofluorescence experiments (Fig. 3a)
and PLAs (Fig. 3b) to assess the intracellular location(s)
of BIN1 and Tau in rat primary neurons. As described in
the literature, Tau was found in the soma and the neur-
ites (Fig. 3a-c), whereas BIN1 was found in the nucleus,
the soma and the neurites (Fig. 3a). Within the neurites,
we observed several puncta corresponding to the putative
co-localization of BIN1-Tau (Fig. 3a). To validate these
results, we used PLAs to detect potentially interacting
BIN1 and Tau molecules (within 28 nm of each other). In
agreement with the immunofluorescence experiments, a
PLA signal for the BIN1 and Tau pair was identified in
both the neuronal soma and the dendrites (Fig. 3b). This
(See figure on previous page.)
Fig. 1 The BIN1-Tau interaction is mediated by the Tau PRD and the BIN1 SH3 domain. a. A schematic linear representation of 2N4R Tau (Tau FL) and
BIN1 isoform1 (BIN1 FL) sequences and their respective domains (as used in GST pull-down assays). MBD: microtubule-binding domain; PRD: proline-rich
domain; Bar: BIN1-amphiphysin-Rvs167; CLAP: clathrin and AP-2 binding; MycBD: Myc-binding domain; SH3: Src homology 3. b. GST pull-down assays
performed with various Tau constructs corresponding to specific Tau subdomains (Lane 2: GST-Tau FL 2N4R; lane3: GST-Tau/Nter[1–152]; lane 4: GST-Tau/
PRD[153–244]; lane 5: GST-Tau/MBD[244–441]) incubated with homogenates from BIN1-overexpressing HEK293 cells (n= 3). Upper panel: A representative
immunoblot of BIN1 pull-down, revealed with a 99D anti-BIN1 antibody. c. GST pull-down assays performed either with full length BIN1 (Lane 2: GST-BIN1
FL) or the BIN1 SH3 domain (lane 3: GST-BIN1/SH3) incubated with homogenates from Tau FL-overexpressing HEK293 cells (n = 3). Upper
panel: A representative immunoblot of Tau pull-down, revealed with a Dako anti-Tau antibody. d. GST pull-down assays performed with
GST-Tau FL (lanes 3 and 4) or GST-Tau/PRD (lanes 5 and 6) incubated with homogenates from HEK293 cells overexpressing either BIN1 FL
(lanes 3 and 5) or a BIN1 construct lacking the SH3 domain (BIN1/ΔSH3, lanes 4 and 6) (n = 3). Upper panel: A representative immunoblot
of BIN1 pull-down, revealed with a 99D anti-BIN1 antibody. Lower panels (B, C, D): the corresponding Coomassie blue gels, used as loading controls for
the pull-down assays. e. Two-dimensional (2D) [1H, 15N] HSQC spectra of 100 μM 15N 2N4R Tau, either free in solution (gray) or with a 1.6 molar amount
of GST-BIN1/SH3 (blue, superimposed): Overlaid details of the full spectra presented in Additional file 3. f. Combined 1H, 15N CS perturbations (δ CS) in
ppm, as defined in the Methods, in [1H, 15N] HSQC spectra of 15N 2N4R Tau with a 1.6 molar ratio of GST-BIN1/SH3 versus the molecule free in solution
for every resonance along the sequence. The dashed box indicates the position of the Tau-F5 fragment within the Tau FL sequence. g. 2D [1H, 15N]
HSQC spectra of 100 μM 15N Tau-F5 [165–245] free in solution (gray) or with a 1.2 molar amount of GST-BIN1/SH3 (red, superimposed): Overlaid details
of full spectra presented in Additional file 4. h. Combined 1H, 15N CS perturbations (δ CS) in ppm, as defined in the Methods, in [1H, 15N] HSQC spectra
of 15N Tau-F5 [165–245] with a 1.6 molar ratio of GST-BIN1/SH3, versus the free molecule in solution and for every resonance along the sequence. i.
The a minima SH3 binding sequence in Tau. Proline residues are shown in bold, residues with resonance broadenings upon interaction are shown in
red and residues with CS deviation when comparing free and bound states are shown in blue. The underlined amino acid residues fit the consensus
sequence for SH3 binding (PxxPx+, where x is any residue and + is a positively charged residue) [30]
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staining pattern contrasted with both the homogeneous
immunofluorescence pattern observed for total Tau (Fig. 3c)
and the strong PLA signal for Tau and tubulin (a major
Tau partner) (Fig. 3d). Lastly, the BIN1-Tau PLA staining
partly co-localized (mean ± standard deviation (SD) co-
localization coefficient: 0.399 ± 0.041) with the actin
cytoskeleton (as revealed by phalloidin staining; Fig. 3e,
f, Additional file 10 and Additional file 11). In add-
itional experiments, we further characterized the sub-
cellular location of BIN1-Tau complexes in primary
neurons (Fig. 4). Firstly, on the basis of the previously
described role of BIN1 in endocytosis, we co-stained
BIN1-Tau complexes and the endocytosis marker clathrin;
the co-localization was very weak (Fig. 4a and Additional
file 10; mean ± SD co-localization coefficient: 0.054 ±
0.014). Likewise, specific pre- or post-synaptic markers of
functional neuronal compartments (such as synaptophysin
(Fig. 4b) and PSD95 (Fig. 4c)) did not co-localize with
BIN1-Tau complexes (mean co-localization coefficient ~0;
see Additional file 10).
In conclusion, these results showed that Tau/BIN1
complexes are found at specific locations in primary
neurons (as suggested by the dot-like staining) and
partly co-localize with the actin cytoskeleton.
Tau’s phosphorylation status influences BIN1-Tau binding
in primary neurons
Since we had observed that Tau phosphorylation within or
close to the Tau/PRD was able to modulate the BIN1-Tau
interaction in vitro, we next looked at whether phosphor-
ylation might modulate the interaction in primary neu-
rons. To this end, we used a PLA that combined a BIN1
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Fig. 2 Tau phosphorylation precludes the BIN1-Tau interaction in vitro. a. Tau-F5 fragment phosphorylation analysis after in vitro phosphorylation by
CDK2/CycA3 kinase. Representative immunoblots using various antibodies against phosphorylation epitopes in Tau. The total amount of Tau-F5 was
revealed by the phosphorylation-independent antibody Tau5. The significant shift in molecular weight observed in CDK2/CycA3-treated samples indicates
Tau hyperphosphorylation. In contrast to other antibodies, the Tau-1 antibody binds to various non-phosphorylated Tau sites; the signal thus decreases
when Tau is hyperphosphorylated [31]. b. 2D [1H, 15N] HSQC spectra of 125 μM 15N CDK-phosphorylated Tau-F5[165–245] free in solution (gray) and
with a 1 molar amount of GST-BIN1/SH3 (red, superimposed): Overlaid details of 2D [1H, 15N] HSQC spectra presented in Additional file 6.
c. 2D [1H, 15N] HSQC spectra of 60 μM 15N CDK-phosphorylated 2N4R Tau free in solution (gray) and with a 2 molar amount of GST-BIN1/
SH3 (blue, superimposed): Overlaid details of full spectra presented in Additional file 7
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antibody with several specific, phosphorylation-dependent
anti-Tau antibodies: an antibody against phosphorylation
sites within Tau’s C-terminal region (pSer396-pSer404)
(Fig. 5a, b) and two antibodies against phosphorylation
sites near to or within the PRD peptide sequence that
interacts with the BIN1/SH3 domain, i.e. pS202 (Fig. 5c,
d) and pT231 (Fig. 5e, f ). A PLA signal was observed with
pSer202 and pSer396-pSer404 antibodies but not with
antibodies against pThr231 (RZ-3, Fig. 5e, and AT180,
data not shown). It should be noted that this difference
cannot be attributed to differences in Tau phosphorylation
levels in the various primary neuron cultures, since con-
ventional immunofluorescence experiments did not high-
light any obvious differences between the staining levels
obtained for all the epitopes studied (Fig. 5b, d, f, g). These
PLA results are in full agreement with those of our NMR
experiments. Hence, in primary neurons, the phosphoryl-
ation status of the Tau/PRD sequence modulates inter-
action with the BIN1/SH3 domain. Moreover, our results
suggest that Thr231 is one of the phosphorylation sites
that modulates this interaction.
Discussion
Progress in genetic analysis (notably in genome-wide
association studies) has led to the identification of 24
validated risk loci for AD [13]. BIN1 is the first of these
risk factors to have been linked to Tau pathology [3]. In
the present study, we used biochemical and cellular ap-
proaches to further characterize the relationship between
Tau and BIN1. Firstly, we found that BIN1’s SH3 domain
interacts directly with the Tau PRD. Secondly, we deter-
mined that the amino acid sequence [212–231] within the
PRD is involved in this interaction. Thirdly, we showed
that Tau phosphorylation weakens the Tau-BIN1 inter-
action both in vitro and in primary neurons. Fourthly, we
found that BIN1-Tau complexes exhibit a co-localization
with the actin cytoskeleton in primary neurons.
BIN1 belongs to the amphiphysin protein family, the
best-known function of which is to sense and generate
membrane curvature through its BAR domain. This pro-
tein is also a key regulator of biological functions such
as endocytosis, membrane recycling and cytoskeleton
regulation [14]. Accordingly, BIN1 recruits some part-
ners (such as AP-2 and clathrin) through its CLAP
domain and others (such as dynamin and synaptojanin)
through its SH3 domain [14]. Tau proteins are
microtubule-associated proteins whose main function is
to promote the polymerization and stabilization of the
cytoskeleton microtubule network [15]. Tau is also in-
volved in cell signaling pathways via the recruitment of
kinases (such as Lck, Fyn, Src [16, 17] and phos-
phatidylinositol 3-kinase) and signaling adaptors (such
as Grb2 [11, 18]). These interactions are mediated by
Tau’s PRD. In the present work, we extended these
results by showing that BIN1-Tau binding occurs through
the SH3 domain and the PRD. Given that Tau phosphoryl-
ation (strong regulator of Tau function) is deregulated in
AD, we sought to determine whether Tau phosphorylation
was involved in regulation of the BIN1-Tau interaction.
Our data indicate that Tau phosphorylation can indeed
modulate the interaction between BIN1 and Tau in vitro.
These results are consistent with previous reports of
phosphorylation-dependent binding between Tau PRD
and SH3 domains in proteins such as phosphatidylinositol
3-kinase, phospholipase C γ1, Grb2, and Src family ki-
nases [11, 18]. Importantly, the results of our NMR and
cell biology experiments suggest that phosphorylation at
Thr231 (which is within the Tau PRD sequence that inter-
acts with the BIN1 SH3 domain) weakens this interaction.
These data are coherent with previous studies showing
that Tau mutants mimicking phosphorylation at Thr231/
Ser235 (T231D/S235D) bind 8 times less avidly (compared
with native Tau) to the SH3 domain of Fyn [18], whereas a
single mutation at Ser235 (S235E) does not affect the
binding [11]. In contrast, mimicking phosphorylation at
Ser396 and Ser404 (S396D/S404D) did not modify the
affinity of 3-repeat Tau isoforms for Fyn/SH3. The latter
literature data are consistent with (i) our PLA staining
results for pS396-404 Tau and BIN1 and (ii) the fact that
3-repeat Tau isoforms are expressed in primary neuron
cultures. Indeed, it has been well established that both
4-repeat and 3-repeat Tau isoforms are expressed in
primary neurons after 14 days of in vitro culture [19].
Moreover, Tau proteins with different phosphorylation
patterns (generated with various kinases) failed to inter-
act with BIN1 in vitro (Fig. 3 and Additional file 8 and
Additional file 9) but all were phosphorylated at Thr231.
This strongly suggests that pThr231 is an important
(See figure on previous page.)
Fig. 3 BIN1-Tau complexes partly co-localize with the actin cytoskeleton network. a. Immunofluorescence staining of endogenous BIN1 (green) and
total Tau (red) in primary neuron cultures. Arrows indicate the co-localization of BIN1 and total Tau staining. b. PLAs (green) were been used to visualize
endogenous BIN1-Tau complexes. Co-staining for total Tau (red) was compared with the PLA (BIN1/total Tau) signal. The arrow indicates the PLA signal
located at the end of microtubule structures. c. Immunofluorescent staining of endogenous tubulin (tub, in green) and total Tau (red) in primary neuron
cultures. d. A PLA (green) for visualizing endogenous complexes between tubulin and total Tau, combined with immunofluorescent staining of total Tau
(red). e. A PLA for BIN1/total Tau (green) was combined with actin staining (red) using Alexa-Fluor633 phalloidin. The arrow shows the location of the PLA
signal, with actin staining . f. A 3D image showing the proximity of the green (BIN1/total Tau) signal to the actin staining. A 3D video is
presented in Additional file 11. Mag: magnification
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regulator of the BIN1/Tau interaction. Indeed, these find-
ings were confirmed by our PLAs, since no interaction was
observed with Thr231-phosphorylated Tau species in pri-
mary neurons. However, since Tau phosphorylation pat-
terns are known to be associated with different subcellular
locations (e.g. low Thr231 phosphorylation at the neuron’s
cortical membrane [20]), one can argue that cell-sorting
mechanisms might be responsible for the lack of interaction
of BIN1 with pThr231 Tau in neurons. However, given that
other sites in pThr231 Tau may also be phosphorylated, we
cannot rule out the possibility that the latter also modify
the BIN1/Tau interaction. Further experiments will be
required to specify the possible contributions of other Tau
phosphorylation sites and identify the mechanisms that
underlie the regulation of the BIN1-Tau interaction by
phosphorylation. Nevertheless, our finding that phosphoryl-
ation of Thr231 strongly influences the BIN1-Tau inter-
action highlights a putative link to the pathogenesis of AD.
Indeed, Thr231 hyperphosphorylation occurs in the very
early stages of neurofibrillary degeneration [21]. The en-
zymes that control this phosphorylation (such as Cdk5 [22],
Gsk3-β [23], PP2A [24] and PIN1 [25]) are markedly
deregulated during the AD process. These findings suggest
that Tau hyperphosphorylation during AD (or at least phos-
phorylation at Thr231) can interfere with the physiological
stoichiometry of BIN1-Tau complexes and may have a par-
ticular impact in the early stages of AD. We and others
have shown that BIN1 expression is elevated in AD brains
[3] and that BIN1 levels are correlated with the presence of
neurofibrillary tangles [26]. Moreover, our previous work
demonstrated that Tau toxicity in Drosophila models was
suppressed by downregulating the Drosophila BIN1 ortho-
log [3]. Although our earlier results suggest that BIN1-Tau
complexes have toxic effects, we cannot yet clearly define
the roles of these complexes in AD or how Tau Thr231
phosphorylation contributes to this pathway during AD
pathogenesis. In order to better understand the role of
BIN1-Tau complexes, we performed experiments with
markers of the various cell compartments involved in fun-
damental neuronal functions (such as synapses and endo-
cytosis). Our results showed that BIN1-Tau complexes did
not co-localize with either pre-synaptic or post-synaptic
terminal markers. Moreover, clathrin (a marker of the
endocytosis pathway) did not particularly co-localize with
BIN1-Tau complexes. These results suggest that BIN1-Tau
complexes exert their functions through cellular pathways
other than the currently known pathogenic pathways
involving Tau at the synapse [27] or involving BIN1 in
endocytosis [14]. Nonetheless, we demonstrated substantial
co-localization of BIN1-Tau complexes and the actin cyto-
skeleton. Therefore, one can postulate that BIN1 and
microtubule-associated Tau have a role at the interface
between actin and the microtubule network in neurons.
Indeed, previous research has found that BIN1 interacts
with the actin cytoskeleton [14] and serves as a membrane
anchoring point for microtubules [28]. Further studies will
be needed to fully understand the roles of BIN1-Tau com-
plexes in neurons.
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Fig. 5 Specific Tau phosphorylation patterns for endogenous BIN1-Tau complexes in primary neuron cultures. A PLA (green) combining anti-BIN1
with either anti-phospho Tau pS396-404 a, pS202 c. or pT231 e antibodies. There was no PLA signal when anti-Tau pT231 was combined with anti-BIN1.
Conventional immunofluorescence staining for BIN1 (cyan) and phospho-Tau (red) obtained with the antibodies used in the PLAs (pS396-404 b, pS202 d
or pT231 f). g. Quantification of PLA fluorescence intensity in three fields and three independent experiments. The graph shows the ratio between the PLA
intensity for BIN1/phosphoTau and phosphoTau alone. (n= 3) AU: arbitrary units. The error bars correspond to the SD
(See figure on previous page.)
Fig. 4 BIN1-Tau complexes are rarely co-localized with clathrin-coated membranes and are not co-localized with synaptic markers. a. A PLA for
Tau-BIN1 (green) and clathrin staining (red) in primary neuron cultures. b. A PLA for Tau-BIN1 (green) and the pre-synaptic marker synaptophysin
(red) in primary neuron cultures. c. A PLA for Tau-BIN1 (green) and the post-synaptic marker PSD95 (red) in primary neuron cultures. Upper panels:
maximum intensity projection. Lower panels: a single confocal Z-stack. Mag: magnification
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Conclusions
Our results show that BIN1’s SH3 domain interacts
directly with the Tau PRD, and that Tau phosphorylation
(notably at Thr231) weakens this interaction. Taken as a
whole, our findings highlight the link between BIN1,
regulation of Tau phosphorylation and AD-related cellu-
lar pathways. Better knowledge of the interactions
between Tau, BIN1 and the cytoskeleton in neurons may
open up some exciting avenues for further research.
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